Serum growth factors stimulate expression of the immediate-early gene set within their target cells. By definition, immediate-early genes are induced at the transcriptional level by growth factors, and the induction is not blocked by drugs that inhibit protein synthesis (1, 23, 27, 28, 41) . Because all components of the transcriptional response preexist within cells, cis-and trans-acting regulatory elements for the immediateearly genes define useful endpoints for analysis of signal transduction. A well-characterized example of a fast immediateearly gene is c-fos. A cluster of three cis-acting regulatory elements contained within the proximal 5Ј flanking sequences of c-fos has proven to be of general interest for problems in growth factor signal transduction. The three functionally distinct elements within the proximal 5Ј flanking sequences of c-fos include a 22-nucleotide region of dyad symmetry, termed the serum response element, a cyclic AMP response element, and an element responsive to platelet-derived growth factor (PDGF) B:B homodimers known as the sis-inducible element (4, 12, 14-16, 44, 47, 48, 50, 51) . Nuclear trans-acting proteins that interact with these cis-acting regulatory elements have been isolated and characterized (10, 31, 32, 35, 36, 49) . By both sequence analysis and functional analysis, the regulatory elements defined initially within c-fos have been detected within other immediate-early genes (7, 33, 37) .
The c-fos gene, however, does not stand as a prototype for all members of the immediate-early gene set. A second cohort of the immediate-early gene set is induced with slower kinetics than c-fos and by distinctly different mechanisms (20, 21) . The first proto-oncogene (c-myc) (25) and the first chemokine gene (JE/MCP-1, hereafter referred to as MCP-1) (8, 39, 40) described are contained within this subset, which we refer to as slow immediate-early genes. PDGF added to quiescent 3T3 cells stimulates transcription of c-fos within 10 min. c-fos transcripts reach peak levels within 30 min and return to baseline within 2 h (17, 26) . In contrast to the rapid but transient response exhibited by c-fos, slow immediate-early genes like c-myc and MCP-1 display a 60-to 90-min lag time for initiation of transcription (9, 18, 26) . Nuclear runoff transcription analysis demonstrates that induction of MCP-1 mRNA by PDGF and serum is primarily the result of increased transcription (18, 20, 24, 38) . No fos-like regulatory elements are found within several kilobases of 5Ј or 3Ј flanking sequences of the MCP-1 gene or within its coding sequences. A major bottleneck for structure-function analysis of the slow immediate-early genes has been obtaining regulated expression in transient transfection studies.
We recently reported a discontiguous pair of cis-acting elements, both of which are essential for regulated expression of the murine MCP-1 gene. One of these elements is a 7-base motif, TTTTGTA, located in the proximal 3Ј MCP-1 untranslated sequences. The mechanism of action of this 3Ј element is unknown. However, identical 7-mers are found in proximal 3Ј untranslated sequences of c-myc, multiple zinc finger transcription factor genes, and multiple cytokines belonging to the immediate-early gene set (13) . The discovery of the essential 3Ј 7-mer facilitated detection of a second required MCP-1 genomic element. The second element was detected as a 240-bp fragment found 2.3 kb upstream of the MCP-1 start of transcription. The 240-bp fragment is sufficient to restore PDGF inducibility (provided that the 3Ј 7-mer is also present) in a position-and orientation-independent manner; i.e., it functions as a classical inducible enhancer element (13) . Furthermore, the 240-bp fragment is sufficient to restore induction of the MCP-1 gene in response to serum, double-stranded RNA, interleukin-1␣ (IL-1␣) or PDGF (13) .
In this report we show that four distinct PDGF-regulated elements are present within the 240-bp enhancer fragment. Two of the elements contain homologous sequences and bind several forms of the transcription factor NF-B. Herein we focus on the other two elements, which appear to be previously uncharacterized, PDGF-regulated protein-binding sequences.
MATERIALS AND METHODS
Growth factors and reagents. The recombinant B:B isoform of PDGF and recombinant IL-1␣ were obtained from Upstate Biotechnology, Inc. RNase A was obtained from Pharmacia. Proteinase K, RNase T 1 , calf intestinal phosphatase (CIP), and poly(dI-dC) were obtained from Boehringer Mannheim Biochemicals. Bovine calf serum was obtained from Hyclone. Human defibrogenated platelet-poor plasma (PPP) was prepared as described previously (34) . Monoclonal antibodies to phosphoserine, phosphothreonine, and phosphotyrosine were obtained from Sigma. Polyclonal antibodies to the p50 and p65 subunits of NF-B, and the peptides that these antibodies were raised against, were obtained from Santa Cruz Biotechnology. Synthetic oligonucleotides were obtained from Macromolecular Resources. Tyrosine phosphatase from Yersinia enterocolitica was obtained from New England Biolabs.
Cell culture, DNA transfections, stimulation assays, and RNA preparation and analysis. NIH 3T3 cells were maintained in Dulbecco's modified Eagle medium (DME medium; Gibco Laboratories) supplemented with 10% bovine calf serum. NIH 3T3 cells were used for transient transfections because of their significantly greater transfection efficiency compared with BALB/c-3T3 cells. Twenty hours prior to transfection, cells were plated at a density of 2.0 ϫ 10 6 per 15-cm-diameter tissue culture dish. Calcium phosphate-mediated DNA transfections were performed as described previously (14) , with the following modifications. Cells were exposed to DNA-containing precipitates for 6 h followed by a 2-min 20% glycerin shock. Cells were then washed with DME and placed in DME plus 5% PPP. Because of variable background levels of MCP-1 transcripts in transfected cells quiesced with 0.5% calf serum, we have found it more useful to use 5% PPP in quiescing transfected cells after the glycerin shock. Transfection mixtures included 50 g of tagged MCP-1 reporter constructs together with 10 g of an alpha-globin reference construct (pSV␣-1), a gift from M. Greenberg (Harvard Medical School), per 15-cm-diameter tissue culture plate. After 40 to 44 h in 5% PPP, stimulated groups of cells were exposed to the B:B isoform of PDGF (30 ng/ml) for 2 h, unless otherwise indicated in the figure legends. Total RNA was prepared by the guanidinium isothiocyanate method and purified on CsCl gradients (5) .
Total RNA samples (30 g per assay for transient transfections and 10 g per assay for endogenous MCP-1 analysis) were analyzed by RNase protection assay as described previously (52) . RNase treatment was done with 60 g of RNase A per ml and 2 g of RNase T 1 per ml for 75 min at 35ЊC. Nuclease-resistant fragments were separated on 8-mm 6% polyacrylamide-8 M urea gels. Synthesis of labelled complementary RNA probes was done as described previously (30) , with pGEM vectors (Promega). Probes were gel purified before use. The probe for tagged MCP-1 expression is a 272-bp HincII MCP-1 cDNA fragment spanning portions of the second and third exons. The fragment is elongated by the addition of a 33-bp tag into a blunted SauI site and inserted into the SmaI site of pGEM 7 (13) . The length of the unprotected probe is 377 bases. As a control for equal transfection efficiencies between groups of cells, 10 g of total RNA was assayed by RNase protection for the presence of a constitutively active cotransfected alpha-globin construct. Exposure and quantitation of gels were done for all experiments on a PhosphorImager (Molecular Dynamics).
Oligonucleotides. The double-stranded oligonucleotides containing 5Ј overhanging GG (top strand) and CC ends (bottom strand) used are shown in Table  1 .
Preparation of nuclear and cytoplasmic extracts and electrophoretic mobility shift assays. Nuclear and cytoplasmic S100 extracts from BALB/c-3T3 fibroblasts (clone A31) were prepared as described by Dignam et al. (11) . Chemically synthesized oligonucleotides were annealed and labelled with 32 P-nucleotides by fill-in with the Klenow fragment of DNA polymerase I. Radiolabelled doublestranded oligonucleotides were gel purified prior to use as probes in electrophoretic mobility shift assays. Binding reaction mixtures contained 10 to 15 g of fibroblast nuclear extracts, radiolabelled oligonucleotide probe (10,000 cpm; 0.1 to 0.25 ng), and 0.5 or 1.5 g of (element III only) poly(dI-dC) in 10 mM Tris (pH 7.5)-5% (vol/vol) glycerin-50 mM NaCl-1 mM EDTA-1 mM dithiothreitol in a final volume of 20 l. Following 50 or 15 min (element III only) of incubation on ice, DNA-protein complexes were electrophoresed on 4% native polyacrylamide gels at 150 V for 2.5 h at room temperature in 0.25ϫ TBE (Tris-borate-EDTA) buffer. For antibody supershift or competition experiments, antibodies or 100-fold excesses of unlabelled oligonucleotides were added for a 30-min incubation on ice prior to the addition of the radiolabelled oligonucleotide probe.
UV cross-linking and DNase I footprinting. UV cross-linking was performed as described previously (6) . Native polyacrylamide gels used for cross-linking experiments were run at 150 V at 4ЊC in 0.25ϫ TBE buffer. DNase I footprinting was performed as described previously (2), with the following modifications. A PDGF-regulated 240-bp SmaI-HincII MCP-1 genomic fragment (13) inserted into the SmaI site of pGEM-7 was used to generate single-strand 32 P-labelled nucleotide probes by fill-in with the Klenow fragment of DNA polymerase I. Footprinting reaction mixtures included 150 g of fibroblast nuclear extracts, 3.3 g of poly(dI-dC), and single-strand radiolabelled probes (20,000 cpm), with the same binding buffer used for electrophoretic mobility shift assays in a final volume of 50 l. After a 30-min incubation on ice, 3 U of DNase I (Promega) was added at room temperature for 1 min. The Mg 2ϩ and Ca 2ϩ concentrations of all footprinting reaction mixtures were adjusted to 5 and 2 mM, respectively, immediately after the addition of DNase I. Following phenol extraction and ethanol precipitation, DNase I digestion reaction mixtures were electrophoresed on 6% acrylamide-8 M urea sequencing gels.
Plasmid construction. A murine MCP-1 genomic clone (pGMJE-1) with 466 bp of 5Ј flanking sequences and 1.9 kb of 3Ј flanking sequences was a gift from B. Rollins (Dana-Farber Cancer Institute). The MCP-1 construct was originally inserted into the EcoRI site of pGEM-1 (39) . A noninducible tagged MCP-1 construct (construct 1 in Fig. 1 and 6 XhoI-ClaI fragment of the pGEM-7 polylinker to a SauI site in the third exon of pGMJE-1 (1,049 nucleotides downstream of the transcription start site). An identical 33-bp tag was inserted into the RNase protection probe vector described above.
Add-back constructs shown in Fig. 1 and 6 were generated by blunt ligation of MCP-1 genomic sequences or double-stranded synthetic oligonucleotides to tagged pGMJE-1 (construct 1 in Fig. 1 and 6 ) opened with SalI. Construct 2 in Fig. 1 and 6 was generated by blunt ligation of a 240-bp SmaI-HincII MCP-1 fragment (with ends at Ϫ2537 and Ϫ2298 bp relative to the MCP-1 start of transcription) to SalI-opened construct 1. Constructs 3, 4, and 5 in Fig. 1 were generated by blunt ligations of 97-bp SmaI-PstI, 143-bp PstI-HincII, and 135-bp DdeI subfragments of the 240-bp fragment to SalI-opened construct 1, respectively. Constructs 3 through 9 in Fig. 6 (top) and the two mutants in Fig. 6 (middle) were generated by blunt ligations of the relevant double-stranded synthetic oligonucleotides corresponding to the wild-type and mutant elements II and III to SalI-opened construct 1. All constructs were checked for accuracy by DNA sequencing (43) .
RESULTS
PDGF induction of MCP-1 involves at least two distinct elements within the distal 240-bp enhancer fragment. Initial experiments were designed to locate a PDGF-responsive genomic element(s) within the 240-bp enhancer fragment. Three subfragments of the 240-bp enhancer fragment were generated, including the distal 97 nucleotides, the proximal 143 nucleotides, and a 135-nucleotide subfragment which overlaps the distal and proximal subfragments (Fig. 1A , constructs 3, 4, and 5, respectively). Readdition of any subfragment restores PDGF inducibility to a truncated MCP-1 reporter construct in transient transfection experiments (Fig. 1B) . Significantly, however, only 30 to 50% of the induction observed with the full 240-bp enhancer is obtained with any one of the subfragments (Fig. 1B) . Since constructs 3 and 4 are both PDGF inducible but contain nonoverlapping subfragments of the 240-bp enhancer, these data demonstrate that at least two PDGF-responsive elements are present within the 240-bp genomic enhancer.
DNase I footprinting and mobility shift assays highlight four PDGF-responsive elements within the 240-bp enhancer fragment. Three regions (designated elements IV, III, and II in Fig. 2 and all subsequent figures) are protected from DNase I digestion by nuclear extracts from PDGF-treated fibroblasts. An additional element (element I in all subsequent figures) is located at the extreme 5Ј terminus of the 240-bp fragment and was detected by its close sequence homology to element IV. Footprints corresponding to elements II and IV display both constitutive and PDGF-inducible components (Fig. 2 , compare lanes 4, 7, and 10 with lanes 3, 6, and 9, respectively). In BALB/c-3T3 cells, the MCP-1 gene is also induced by IL-1␣ (13, 19) . For comparative purposes, we conducted footprint analysis using nuclear extracts from IL-1␣-treated cells. As shown in Fig. 2 , the IL-1␣ and PDGF footprint patterns are indistinguishable. An additional protected region, detected between elements III and IV in Fig. 2 , did not bind any nuclear protein(s) in mobility shift assays and was not studied further (data not shown). Synthetic oligonucleotides corresponding to elements I through IV were employed as double-stranded DNA probes in mobility shift assays. By using nuclear extracts from quiescent and PDGF-treated fibroblasts, at least one PDGF-inducible complex is noted in mobility shift assays using each individual element as the probe (Fig. 3) . Consistent with the DNase I footprints, binding to elements II and IV exhibits both constitutive binding and PDGF-inducible binding components (Fig .   FIG. 4 . Characterization of the four MCP-1 genomic elements by competition analysis and antibody supershifts in mobility shift assays. A schematic diagram of the 240-bp MCP-1 enhancer fragment is shown at the top of each panel. Position 1 is at the 5Ј end of the fragment. The relative positions of the four elements with respect to the nonoverlapping 97-and 143-bp subfragments are shown. A shaded oval denotes the probe used in the mobility shift assays shown in each panel. Sequences of all double-stranded oligonucleotides used in competition assays are given in Materials and Methods. Double-stranded oligonucleotide competitors were added in 100-fold excess for all competition assays. Rabbit polyclonal antibodies (2.5 g) raised against the 50-kDa subunit (p50) or 65-kDa subunit (p65) of NF-B were used for supershifts. Control peptides for each antibody (1 g) were added where indicated. P denotes probe alone. NA denotes no extract added. A radiolabelled double-stranded oligonucleotide probe corresponding to element I (A), II (B), III (C), or IV (D) was used in mobility-shift assays with 15 (A, B, and D) or 10 (C) g of nuclear extracts prepared from fibroblasts treated with the B:B isoform of PDGF (30 ng/ml) for 1.75 h (ϩ).
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3). In contrast to the footprint analysis, PDGF-inducible binding to element III is seen in mobility shift assays (compare Fig.  2 , lanes 3 and 4, 6 and 7, and 9 and 10, with binding to element III in Fig. 3 ). One explanation for this apparent discrepancy comes from determining differences in ''on'' rates of binding to element III between quiescent and PDGF-treated nuclear extracts. PDGF-treated nuclear extracts have significantly greater on rates of binding to element III than nuclear extracts from quiescent fibroblasts (data not shown). For footprint analysis, larger amounts of each nuclear extract were added for longer binding incubations, thereby obscuring the differences in rates of protein binding to element III. Elements I and IV are related to each other and bind one or more forms of the transcription factor NF-B. In mobility shift assays, oligonucleotides corresponding to elements I and IV compete for binding to themselves and each other ( Fig. 4A and  D) . Oligonucleotides containing two different NF-B-binding sequences (designated NF1 and NF2 [ Fig. 4 ]) also compete for binding to elements I and IV. Polyclonal antibodies specific for the p50 and p65 subunits of NF-B supershift several of the complexes which bind elements I and IV ( Fig. 4A and D) . Specificity of antibody supershifts is demonstrated by removal of supershifts with addition of peptides used in generation of the antibodies (Fig. 4A and D, upper two arrows) . Interestingly, neither element I nor NF-B-related oligonucleotides compete for specific binding of a noninducible complex to element IV (Fig. 4D, bottom arrow) .
Elements II and III are novel binding sequences and require at least 15 and 18 nucleotides, respectively, for PDGF-inducible binding to occur. Only oligonucleotides corresponding to the shift probes themselves compete for binding to elements II and III. No competition was observed with oligonucleotides (i) corresponding to element IV or (ii) containing two distinct NF-B-binding sites ( Fig. 4B and C) . Oligonucleotides corresponding to element I are also unable to compete with binding to elements II and III (data not shown). No supershifts were observed with anti-p50 or anti-p65 antisera ( Fig. 4B and C) . Further experiments focused on elements II and III.
Steric hindrance of DNase I activity by proteins binding specifically to DNA in footprinting reactions is known to result in overestimation of the true size of protein-binding sequences. Mobility shift assays using several deletion probes of elements II and III were therefore used to more precisely delineate the sequences within elements II (which footprints as a 27-mer) and III (which footprints as a 28-mer) required for PDGFinducible binding. Deletions of up to 7 nucleotides at the 3Ј end of element II do not alter PDGF-inducible binding (Fig. 5,  center) . In contrast, deletion of a 5-nucleotide CCTTT sequence at the 5Ј end of element II, or 11 nucleotides at the 3Ј end of element II, eliminates PDGF-inducible binding (Fig. 5,  center) . These data suggest that PDGF-inducible binding to element II requires some portion of the 5Ј CCTTT sequence. By using a probe with smaller 5Ј and 3Ј deletions, PDGFinducible binding to element II is shown to require at least 15 nucleotides (Fig. 5, center ; compare binding to probe 5D2/ 3D10, a 15-mer, with binding to unaltered element II probe).
Deletion of 8 nucleotides at the 5Ј end of element III, or 5 nucleotides at the 3Ј end of element III, eliminates PDGFinducible binding to element III (Fig. 5, bottom) . Deletion of 5 nucleotides at the 5Ј end of element III reduces, but does not eliminate, PDGF-inducible binding to element III (Fig. 5, bottom ). These data demonstrate that PDGF-inducible binding to element III is diminished or eliminated by 5-nucleotide deletions at the 5Ј or 3Ј ends of element III, suggesting that PDGFinducible binding to element III requires at least 18 nucleotides. PDGF-inducible binding to element III is also eliminated by an 8-base mutation within element III (Fig. 5,  bottom) .
Sequence comparison revealed no known transcription factor-binding sequences closely matching the minimal sizes of elements II and III determined in Fig. 5 . In particular, neither element contains sis-inducible factor-binding sequences (51) . A potential AP-1-binding site is present within the minimal required element II-binding sequences delineated above. Mobility shift experiments using a labelled AP-1 oligonucleotide probe, however, did not yield complexes similar to those seen with the element II probe (data not shown). Because elements II and III appear to be novel PDGF-regulated DNA-binding elements, further experiments focused on their properties. Readdition of a single copy of element II is sufficient to restore PDGF inducibility to a noninducible MCP-1 reporter gene. In add-back experiments, a single copy of element II, in either orientation, is sufficient to restore PDGF inducibility to a truncated, noninducible MCP-1 gene (Fig. 6, top panel; compare the stimulated lanes of constructs 6 and 7 with construct 1). A single copy of element II functions as well as the large 135-bp subfragment (described in Fig. 1 ) that contains both elements II and III (Fig. 6, top panel; compare the stimulated lanes of constructs 6 and 3). With neither readdition are the resulting PDGF inductions equal to the induction obtained with the complete 240-bp enhancer fragment (Fig. 6, top panel; compare the stimulated lanes of constructs 6 and 3 with construct 2). No further increases in induction are obtained with readdition of two copies of element II or with readdition of single copies of elements II and III together (Fig. 6 , top panel; compare the stimulated lanes of constructs 6, 8, and 9). Lastly, readdition of two copies of element III restores PDGF inducibility (Fig. 6 , top panel, compare the stimulated lanes of constructs 5 and 1).
Readdition of a single copy of element III to the noninducible MCP-1 reporter gene does not restore PDGF inducibility (Fig. 6, top panel; compare the stimulated lanes of constructs 4 and 1). Likewise, readdition of a single copy of element I to the same noninducible MCP-1 reporter gene does not restore PDGF inducibility (data not shown). Taken together, these results suggest that readdition of a single copy of element II specifically restores PDGF inducibility, rather than creating a nonspecific spacer artifact.
These experiments do not address directly whether element III is necessary for a small portion of the full MCP-1 induction observed in response to PDGF stimulation. That such a contribution by element III is minimal is strongly suggested by the result that equal PDGF inductions are obtained with constructs 6 and 3 (Fig. 6, top panel) . Construct 3 contains the 135-bp subfragment (described in Figure 1 ), which includes elements II and III in their in vivo positions and orientations, as well as substantial amounts of flanking sequences. Were there a synergistic interaction between elements II and III, construct 3 would be expected to be inducible to a greater extent than construct 6.
Mutational analysis of element II. Two site-directed mutants of element II were generated. In one mutant (mut1) the extreme 5Ј end of element II is altered. The 5Ј end of element II is shown in Fig. 2 to be part of a PDGF-inducible footprint delineating element II. In the second mutant, bases 13 to 20 of element II (mut2) are altered. Wild-type sequences altered in both mutants are required for PDGF-inducible binding to element II (Fig. 5) . Using either element II mutant as a competitor in mobility shift assays (at a 100-fold excess) resulted in no significant decreases in PDGF-inducible binding to element II (data not shown). The sequences of both mutations are given in Materials and Methods.
Time courses of PDGF stimulation, using add-back constructs containing wild-type element II or the two site-directed mutants in transient transfections, were determined (Fig. 6 , middle and bottom panels). PDGF stimulation of an MCP-1 add-back construct containing a single copy of wild-type element II parallels the initial kinetics of endogenous MCP-1 induction with maximal induction at 1 h of PDGF addition but exhibits greater decreases in MCP-1 RNA levels at 3 and 4.5 h of stimulation (Fig. 6, middle and bottom panels) . In contrast, mutants 1 and 2 exhibit considerably decreased PDGF inductions at 1 h of stimulation (91 and 79% decreases, respectively, RNA levels are maximally elevated at 1 h but remain at these levels through at least 3 h of PDGF stimulation (Fig. 6 , middle and bottom panels). This is in contrast to the wild-type element II-containing construct, which exhibits a marked decrease in MCP-1 RNA levels by 3 h of PDGF stimulation. These differences could reflect a small degree of similar PDGF-inducible proteins binding in vivo to both mutants and wild-type element II. Alternatively, PDGF induction of each mutant-containing construct could reflect activation of transcription through a different enhancer present in the mutants (such as the minimally altered AP-1 site present in each mutant). It should be noted that endogenous MCP-1 RNA levels remained elevated for at least 4.5 h of PDGF stimulation, whereas MCP-1 levels from the transfected wild-type element II-containing construct returned to near baseline levels by 4.5 h of stimulation (Fig. 6 , middle and bottom panels). Hence, a single copy of element II alone is capable of restoring the initial high degree of MCP-1 induction in response to PDGF but is not responsible for the sustained component of MCP-1 induction after PDGF stimulation. In summary, two element II mutants which do not inhibit PDGF-inducible binding to element II confer significantly decreased PDGF inducibility to a truncated noninducible MCP-1 construct (Fig. 6, middle and bottom panels) . These data establish a strong association between PDGF-inducible pro- (Fig. 7A) . A small increase in binding to element II is also observed in nuclear extracts from CHX-treated fibroblasts (Fig. 7A) . Changes in binding to element II in mobility shift assays closely parallel changes in MCP-1 RNA levels from fibroblasts treated with CHX, PDGF, or both (compare binding in Fig. 7A , left panel, with that in Fig. 7B ). In contrast, binding to element III in mobility shift assays is equal in nuclear extracts prepared from fibroblasts treated with CHX, PDGF, or both, a result that correlates poorly with the differences in MCP-1 RNA levels shown in Fig. 7B .
PDGF-inducible binding to element II in mobility shift assays occurs with delayed kinetics. Significant increases in binding to element II are seen with nuclear extracts from fibroblasts treated with PDGF for at least 60 min (Fig. 8A, left panel) . MCP-1 RNA induction after PDGF treatment occurs with similarly delayed kinetics (compare binding changes in Fig. 8A , left panel, with changes in MCP-1 RNA levels in Fig. 8B ). In contrast, PDGF-stimulated binding to element III in mobility shift assays is nearly maximal after a 15-min treatment of fibroblasts with PDGF (Fig. 8A, right panel) . It should be noted that the kinetics of MCP-1 induction in BALB/c-3T3 cells upon PDGF stimulation are more delayed than in NIH 3T3 cells (Fig. 6, middle and bottom panels, and 8B ). The reason(s) for these slight differences is unknown. (Fig. 9) . Whether the 62-and 68-kDa proteins are related to each other structurally is unknown at this time. No cross-linking is observed in the absence of UV irradiation of the gel (data not shown). PDGF-inducible binding to element II is present in nuclear extracts only. Nuclear and cytoplasmic extracts from either quiescent or PDGF-treated fibroblasts were used in mobility shift assays. PDGF-inducible (upper complex) binding to element II in mobility shift assays is detected in nuclear extracts only (Fig. 10, left panel) . In contrast, noninducible (lower complex) binding to element II is present in both nuclear and cytoplasmic extracts (Fig. 10, left panel) .
PDGF-inducible binding to element III in mobility shift assays is also present in nuclear extracts only (Fig. 10, right  panel) . As a control for integrity of the cytoplasmic extracts used in these experiments, we assayed for binding of NF-B, a transcription factor known to be activated in the cytoplasm after a stimulus with subsequent translocation to the nucleus (3, 29) . PDGF-inducible binding of NF-B to elements I and IV in mobility shift assays is seen with all cytoplasmic extracts used in these experiments (data not shown).
PDGF-inducible binding to element II involves a serine/ threonine phosphoprotein. Nuclear extracts from PDGFtreated fibroblasts were used in mobility supershift assays in conjunction with three monoclonal antisera specific for the phosphorylated forms of serine, threonine, and tyrosine. PDGF-inducible (upper complex) binding to element II is supershifted, in a dose-dependent manner, in the presence of monoclonal anti-phosphoserine or anti-phosphothreonine antibodies (Fig. 11A) . PDGF-inducible binding to element II is A radiolabelled double-stranded oligonucleotide probe corresponding to element II was used in mobility-shift assays with 15 g of nuclear extracts prepared from fibroblasts treated with the B:B isoform of PDGF (30 ng/ml) for 1.75 h (ϩ). S, monoclonal antiphosphoserine antibodies added to supershifts (11 and 22 g in lanes 4 and 5, respectively); Th, monoclonal antiphosphothreonine antibodies added to supershifts (9 and 18 g in lanes 6 and 7, respectively); Ty, monoclonal antiphosphotyrosine antibodies added to supershifts (10 and 23 g in lanes 8 and 9, respectively); BSA, bovine serum albumin added (25 and 100 g in lanes 10 and 11, respectively); Azide, sodium azide added to a final concentration of 0.05%; P, probe alone. (B) Radiolabelled double-stranded oligonucleotide probes corresponding to elements II and III were used in mobility-shift assays with 15 g (element II) or 10 g (element III) of nuclear extracts prepared from quiescent fibroblasts (Ϫ) or fibroblasts treated with the B:B isoform of PDGF (30 ng/ml) for 1.75 h (ϩ). CIP pretreatment (1 U per l) was done for 30 min at 30ЊC. P, probe alone; NA, no extract added. An 8.7-or 2.9-fold increase in upper complex binding to element II or III, respectively, after PDGF-stimulation was observed in the absence of CIP pretreatment.
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not affected by the addition of monoclonal anti-phosphotyrosine antisera (Fig. 11A) . As each of the monoclonal antisera is provided as ascites fluid, the latter results with monoclonal anti-phosphotyrosine antisera constitute a control for the specificity of the supershifts noted with the monoclonal anti-phosphoserine and anti-phosphothreonine antibodies. In contrast, lower complex (noninducible) binding to element II is not supershifted with any of the antisera (Fig.  11A) . Additional experiments addressed whether phosphorylation is necessary for binding to element II. Pretreatment of nuclear extracts from quiescent or PDGF-treated fibroblasts with CIP completely removed PDGF-inducible (upper complex) binding to element II (Fig. 11B) . In contrast, noninducible (lower complex) binding to element II is not removed by CIP treatment (Fig. 11B) . Similar results are seen with CIP treatment of PDGF-inducible proteins binding to element III (Fig. 11B ). As a control for possible nonspecific proteolysis resulting from CIP treatment, binding of NF-B in mobility shift assays was examined. No significant decreases in PDGF-inducible NF-B binding in mobility shift assays are seen after treatment with CIP (data not shown). Finally, pretreatment of nuclear extracts from PDGF-treated fibroblasts with a tyrosine phosphatase derived from Y. enterocolitica did not remove PDGF-inducible binding to element II (data not shown).
DISCUSSION
A new PDGF-regulated genomic element mediates induction of the MCP-1 gene. cis-and trans-acting regulatory elements for c-fos and other fast immediate-early genes have been well characterized (22, 42, 46, 51) . The mechanism(s) underlying PDGF-mediated induction of a large second class of immediate-early genes, induced with slower kinetics than the c-fos gene and including the c-myc and MCP-1 genes, is less well resolved. Herein we describe a pair of novel PDGF-regulated cis-acting elements (elements II and III) that mediate MCP-1 induction. Readdition of a single copy of element II restores PDGF inducibility to an otherwise noninducible MCP-1 reporter construct (Fig. 6) . Element III restores PDGF inducibility only when added back in two copies. Although element III is therefore likely to be silent in PDGF-mediated induction of MCP-1 (which contains only one copy of element III), other genes containing two copies of this element could be PDGF inducible. Both elements are contained within a 240-bp enhancer fragment found 2.3 kb upstream of the MCP-1 start of transcription.
Two additional PDGF-responsive cis-acting elements are also present within the 240-bp MCP-1 enhancer. Both elements (I and IV) contain homologous sequences and bind several forms of the transcription factor NF-B. In addition, element IV also binds a noninducible protein complex which does not bind to element I (Fig. 4) . Readdition of a single copy of element IV or two copies of element I is sufficient to restore PDGF inducibility to a noninducible MCP-1 reporter construct (data not shown). Readdition of single copies of element II or IV to a noninducible MCP-1 reporter gene restores in each case approximately 50% of the full level of PDGF induction obtained with readdition of the complete 240-bp enhancer (Fig. 6 , top panel, and data not shown). Taken together, these data suggest that PDGF induction of MCP-1 proceeds through two independent pathways in fibroblasts. One pathway involves activation of the widely present transcription factor NF-B. A second pathway involves activation through a novel genomic element (element II). NF-B has also been suggested recently to be involved in IL-1␣-and tumor necrosis factor alphamediated induction of the MGSA/gro (or KC) gene (45) .
PDGF-inducible binding to element II includes a 30-kDa protein and a serine/threonine phosphoprotein. UV crosslinking experiments detect a single 30-kDa protein in the PDGF-inducible (upper) element II binding complex (Fig. 9) . PDGF-inducible binding to element II is detected only in nuclear extracts (Fig. 10) and is specifically supershifted with monoclonal antibodies to phosphoserine and phosphothreonine (Fig. 11) . Additionally, CIP pretreatment selectively removes the PDGF-inducible upper element II-binding complex (Fig. 11) . Taken together, these data suggest that the PDGFactivated binding to element II includes one or more nuclearrestricted serine/threonine phosphoproteins and that a phosphate group(s) is required for PDGF-activated binding to element II. Whether the 30-kDa protein (p30) detected by UV cross-linking is identical to the serine/threonine phosphoprotein detected in the antibody supershift experiments is unknown at this time. Significantly, after treatment with PDGF, (i) stimulation of binding to element II in nuclear extracts and (ii) induction of MCP-1 gene expression occur with similar delayed time courses (Fig. 8) .
Two mutants of element II which confer decreased PDGF inducibility, as well as significantly different kinetics of induction, to a truncated noninducible MCP-1 construct in transient transfections were generated (Fig. 6, middle and bottom) . The element II mutants neither compete with PDGF-inducible (p30) binding to element II in mobility shift assays nor bind complexes comigrating with the PDGF-inducible p30-containing complex when used as the probe in mobility shift assays (data not shown). Taken together, these data are strongly consistent with a causal relationship between PDGF-inducible protein(s) binding to element II and PDGF-mediated induction of MCP-1 RNA.
We propose the following model for PDGF induction of MCP-1 in BALB/c-3T3 fibroblasts. Binding of PDGF to its membrane receptor initiates a signal culminating in phosphorylation of an intranuclear 30-kDa protein (p30) on serine and threonine. Time course studies (Fig. 8 ) suggest a 1-h delay in phosphorylation of p30, possibly due to delayed initiation of second messenger generation at the receptor level or to a complex intracytoplasmic sequence of reactions preceding phosphorylation of p30. Active phosphorylated p30 binds to element II and can then cooperate with proximal transcription machinery to initiate transcription of MCP-1. Whether p30 binds element II as a single molecule or as a dimer is unknown at present. Additional 62-and 68-kDa element II-binding proteins are present in both nuclear and cytoplasmic compartments but do not appear to be a part of the PDGF-inducible complex binding element II and are therefore not likely to play a role in PDGF induction of MCP-1 (Fig. 9 ). At present we cannot exclude the possibility that more than one phosphoprotein is involved in PDGF-inducible binding to element II. While this model is not the only one consistent with the results presented herein, it is the simplest.
Given the marked differences in kinetics of PDGF induction between c-fos and MCP-1, it is not surprising that the mechanisms of PDGF induction for the two immediate-early genes appear to share few details in common. Lastly, given the general role that the serum response element and sis-inducible element sequences appear to play in serum and PDGF induction of many fast immediate-early genes, it is tempting to speculate that element II may play a similar general role for multiple members of the slow-kinetics subset of immediateearly genes in addition to MCP-1. 
